Fig. 2: Nalm6 tumor killing in NSG mice. | Nature Communications

Fig. 2: Nalm6 tumor killing in NSG mice.

From: Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Fig. 2

a Immunodeficient NSG mice were injected with 1 × 106 Luc+ Nalm6 cells via the tail vein and were followed by BLI. Some mice then received allo CAR T cells or HIP CAR T cells (n = 5 mice in each group in one experiment) intravenously on day 3. Spleen and bone marrow were taken after 27 or 63 days. b BLI images show the tumor burden for all mice in this study. c, d Graphs show BLI signals for animals in the HIP CAR T (c) and allo CAR T cell groups (d, mean ± SEM, n = 5 animals per group). e, f The percentage of CAR+ cells in the bone marrow (e) and spleen (f) were assessed on the day of organ recovery (mean ± SD, n = 5 animals per group). There were no significant differences between the two CAR T cell groups at the same dose level. g The percentage of CD19+ cells in the bone marrow was assessed on the day of recovery (mean ± SD, n = 5 animals per group). For (e–g): Unpaired, two-tailed Student’s t test was used to compare the allo and HIP CAR T cell groups at the same dose level, and no differences were found.

Back to article page